About: http://data.cimple.eu/news-article/905000665b50d87bd4fd95ba7911305089ef52e45cfc67b6c5448cbc

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/905000665b50d87bd4fd95ba7911305089ef52e45cfc67b6c5448cbc Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	The EU's medicines regulator said Thursday it has started a review of US drug maker Eli Lilly's mix of two synthetic antibodies to treat high-risk Covid-19 patients. The company says trials have shown that bamlanivimab and etesemivab reduce hospitalisations and deaths in coronavirus patients. The European Medicines Agency (EMA) said it had started a "rolling review" of the two antibodies used in combination, and of bamlanivimab used alone. The start of the rolling review is a precursor to accelerated authorisation for use within the 27-nation European Union. "The decision to start the rolling review is based on preliminary results from two studies," the Amsterdam-based regulator said. The EMA has started evaluating the first batch of data, which come from animal studies, it said. Bamlanivimab and etesemivab are monoclonal antibodies, which are lab-made versions of the body's natural infection-fighting defences. Giving people ready-made antibodies can help those who are at high risk of severe disease because of weak immunity or underlying conditions. Many scientists have welcomed their Covid fighting potential, and both Lilly and biotech firm Regeneron have received emergency use authorisations in the United States for their treatments. But their uptake has been limited by factors including a lack of patient interest, and not enough staffing and places inside hospitals to administer them. The two antibodies have been designed to attach to the spike protein of the coronavirus at two different sites, stopping it from entering the body's cells, the EMA said. Eli Lilly said on Wednesday that the combination of bamlanivimab and etesemivab reduced hospitalisations and deaths in high-risk patients recently diagnosed with Covid-19 by 87 percent in trials. The new results added to previous data reported by the company in January which used different dosing levels for the two antibodies and also showed a drastic risk reduction. jhe/dk/spm
schema:headline	EU watchdog reviewing Lilly Covid treatment
schema:mentions	Eli Lilly and Company European Medicines Agency Protein Immune system European Union Coronavirus disease United States Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Monoclonal antibody
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-03-11 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	85 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software